The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
volumes for DecisionDx-Melanoma and TissueCypher and expecting 2025 revenue to exceed US$340 million, above prior guidance. The company also launched its AdvanceAD-Tx test for moderate-to-severe atopic dermatitis, signaling a move into a new dermatology segment that could broaden its addressable market and further diversify its test portfolio. We'll now examine how the stronger-than-expected 2025 revenue outlook and test volume growth might reshape Castle Biosciences' investment narrative. These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Castle Biosciences, you need to believe its expanding menu of molecular tests can turn strong volume growth into durable, profitable revenue. The preliminary 2025 update, with double digit volume gains in core tests and revenue now expected above US$340,000,000, reinforces the near term catalyst around broader cli
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 ResultsGlobeNewswire
- Castle Biosciences (NASDAQ:CSTL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- CSTL's page on the SEC website